Systemic Lupus Erythematosus and Accelerated Aging (LUPAGE)

University Hospital of Bordeaux

Status: Enrolling

Conditions: Systemic Lupus Erythematosus

Treatments: Biological: blood sample

Study type: Interventional

Funder types: Other

Identifiers

NCT05698173

CHUBX 2022/53

Details and patient eligibility

About

The study aims at evaluating the phenomena of immune system aging in patients with Systemic lupus erythematosus.

Full description

Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by a breakdown of tolerance against nuclear antigens. Thanks to improvements during the last decades in diagnosis, therapeutics and medical care, the lifespan of SLE patients has remarkably increased. However, standardized mortality ratio are still high in this population, with an increased mortality and morbidity associated with cardiovascular events and infectious events. Interestingly, these conditions are more commonly found during old age in the general population, raising the question of the presence of an acceleration of the aging process in SLE patients.

It has been demonstrated that the aging of the immune system, i.e. immunosenescence, is a key player in the development of many age-related diseases. The acceleration of immunosenescence, as it is observed during chronic viral infections for example, could favor the premature occurrence of clinical manifestations of accelerated aging. The exact contribution of such phenomenon in the context of SLE has, so far, never been explored.

Here, the investigators propose to perform a comprehensive study of the phenomena of immune system aging in patients with SLE in comparison to age-matched healthy controls.

The study will recruit 50 SLE patients followed in Bordeaux University Hospital. Among classical disease activity information, blood samples will be collected at study visit to extensively evaluate immune system aging. Fundamental research will be realized on patients' samples. Patients will be included within their usual follow-up. No extra visit will be needed, and blood samples will be drawn at the same time as those drawn for clinical purposes.

Enrollment: 75 estimated patients

Sex: All

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• male or female;
• age between 18 and 60 years;
• Lupus patient : diagnosis of systemic lupus erythematosus according to ACR or SLICC criteria;
• being affiliated to health insurance;
• willing to participate and to sign informed consent.

Exclusion criteria

• pregnant or breastfeeding women;
• persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

75 participants in 2 patient groups

Systemic Lupus Erythematosus

Experimental group

Description:

Diagnosis of systemic lupus erythematosus according to American College of Rheumatology (ACR) or SLICC criteria

Treatment:

Biological: blood sample

Biological: blood sample

Controls

Other group

Description:

Healthy controls

Treatment:

Biological: blood sample

Biological: blood sample